Physician profile
Richard J Capiola
NPI 1124146055
$3,067.05
in general payments reported to CMS, 2019-2025
10 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $386 · 2021: $688 · 2022: $458 · 2023: $725 · 2024: $216 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $878.81 | 2020-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $622.25 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $411.50 | 2021-2023 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $323.70 | 2021-2023 | Austedo Xr, Austedo |
| Allergan, INC. | $248.22 | 2019-2020 | |
| Axsome Therapeutics, INC. | $222.30 | 2024-2025 | Auvelity |
| Indivior INC. | $126.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $119.63 | 2019 | |
| Alkermes, INC. | $93.59 | 2019 | |
| Sunovion Pharmaceuticals INC. | $21.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Capiola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.